Medicare coverage for semaglutide has two importantly different pathways in 2026: normal Medicare Part D prescription coverage for medically accepted indications and the new Medicare GLP-1 Bridge, a short-term demonstration for certain qualifying weight-management prescriptions. The Bridge began July 1, 2026, and CMS currently specifies an end date of December 31, 2027.
The Bridge is not a universal semaglutide subsidy. CMS lists Wegovy injection and tablets, Foundayo and specifically Zepbound KwikPen as eligible products for the demonstration. Ozempic is not a Bridge product, and the program excludes people whose prescriptions are for conditions covered through ordinary Part D, subject to the detailed CMS eligibility criteria. Review Wegovy forms for brand-specific identity; this page focuses on federal payment pathways.
An eligible Bridge monthly supply carries a $50 beneficiary copay under CMS’s current program, but access depends on a separate prior authorization, patient qualifications and product-specific claim rules. The $50 does not count toward ordinary Part D true out-of-pocket costs. These claims and dates reflect CMS guidance checked October 18, 2026, and must be rechecked before any real enrollment or pharmacy decision.
Standard Part D evaluates medically accepted indications under a member’s actual prescription drug benefit, including formulary status and plan utilization rules. For example, a GLP-1 used to treat type 2 diabetes may be considered through Part D, while a Wegovy prescription for another Part D-coverable indication may also be routed to the plan.
The Medicare GLP-1 Bridge targets a separate weight-management use and operates outside the Part D coverage and payment flow. A beneficiary cannot simply choose the Bridge because a Part D claim was denied for a condition CMS considers Part D-coverable.
Start with why the drug is prescribed, not with the anticipated copay. A product’s appearance in the Bridge list does not make its other indications eligible under the demonstration.
The matrix is a routing guide based on CMS guidance; no row establishes individual eligibility.
| Question | Medicare Part D | Medicare GLP-1 Bridge |
|---|---|---|
| Primary purpose | Medically accepted covered indications under Part D | Qualifying reduction and maintenance of excess body weight |
| Eligible products | Depends on Part D benefit and accepted indication | Wegovy forms, Foundayo, Zepbound KwikPen as specified by CMS |
| Ozempic | May be evaluated for eligible Part D uses | Not listed as Bridge product |
| Authorization | Plan-specific review and utilization controls | CMS demonstration clinical authorization |
| Member cost | Plan deductible and cost-sharing rules | Qualified $50 monthly supply copay |
| Part D cost accumulation | Regular Part D accounting rules | Bridge copay does not count toward TrOOP |
| Dates | Ongoing Part D benefit subject to plan rules | July 1, 2026–December 31, 2027 currently |
As of CMS’s August 2026 program update, the Bridge lists all specified Wegovy formulations, Foundayo and Zepbound KwikPen. Other Zepbound package types such as single-dose vials and single-dose pens are not included in the published Bridge list. Specific NDCs are subject to CMS updates.
Ozempic should not appear in a Bridge purchase claim or patient eligibility promise. Product-specific supply still requires a valid prescription and an appropriate dispensing pharmacy. For alternatives, Foundayo and Zepbound purchase information address their usual legal acquisition separately.
CMS requires an adult age 18 or older and a prescription for weight reduction and maintenance together with ongoing lifestyle modification. At initiation of GLP-1 therapy, eligibility can include a BMI of at least 35; a BMI of at least 30 with a specified diagnosis such as heart failure with preserved ejection fraction, qualifying uncontrolled hypertension or stage 3a-or-higher chronic kidney disease; or a BMI of at least 27 with specified conditions such as prediabetes, prior myocardial infarction, prior stroke or symptomatic peripheral artery disease.
These are examples of the actual CMS branches, not a personalized eligibility determination. The provider must attest to the complete criteria in a Bridge authorization request. CMS also applies restrictions involving Part D-covered conditions and relevant prior Part D GLP-1 use; applicants should not assume meeting a BMI threshold is enough.
CMS explains that type 2 diabetes, moderate to severe obstructive sleep apnea, and certain noncirrhotic MASH indications are within the Part D-coverable category. A beneficiary with those diagnoses may be ineligible for the Bridge even if the plan denies the particular drug, because the program is not intended to replace Part D for these conditions.
For cardiovascular indications CMS also instructs that a prescription intended to reduce major adverse cardiovascular events belongs in Part D rather than the Bridge. The correct route depends on the clinical purpose and CMS rules, not how an advertisement frames the drug.
The specified $50 is the eligible beneficiary’s monthly copay for a Bridge-furnished qualifying drug; it is not the market list price of Wegovy or a guaranteed rate for all Medicare users. CMS says Part D deductibles do not apply, and the Bridge payment does not count toward Part D true out-of-pocket accumulation. Standard Part D low-income subsidy treatment does not reduce this separate Bridge copay.
Commercial manufacturer coupon programs cannot be layered onto Bridge claims under the CMS program rules. Do not extrapolate the Bridge amount to Ozempic, Medicaid beneficiaries outside eligible Part D enrollment or commercially insured shoppers.
For a medically accepted Part D indication, check the member’s current drug plan, exact prescription, formulary, prior authorization, network pharmacy and out-of-pocket estimate. A product not immediately on formulary can have plan-specific coverage determination and exception processes.
The Ozempic insurance guide discusses its product-level details, while insurance overview contrasts payer categories. The Bridge does not remove Part D appeal rights for Part D claims.
Use the current CMS and Medicare GLP-1 Bridge product list rather than a manufacturer announcement or a general GLP-1 chart. Confirm whether a prescription is Wegovy injection or tablets, Foundayo tablets or Zepbound KwikPen; Zepbound single-dose vials and pens are not the same covered package. The list and NDC processing criteria may be revised during this temporary program.
The separate question is whether the beneficiary meets all program criteria, including Part D enrollment, age, relevant diagnoses and the exclusion for specified Part D-coverable conditions. A $50 price shown for someone else does not establish that the applicant or their prescribed presentation qualifies.
Ask whether the issue relates to eligibility, listed product form, clinical authorization, a prior Part D GLP-1 fill or pharmacy claim processing. The correct remedy depends on the reason, and a valid prescription does not require CMS to approve demonstration coverage.
If the problem is a pharmacy change rather than eligibility, the transfer checklist may help coordinate with the pharmacist. Do not buy an unapproved imported product to replace a rejected Bridge claim.
Wegovy and other eligible GLP-1 drugs carry important product-specific warnings and contraindications. For semaglutide products, labeling includes the boxed warning concerning thyroid C-cell tumors and contraindications involving a personal or family history of medullary thyroid carcinoma or MEN 2. Clinicians must evaluate these issues regardless of the program copay.
The Bridge’s access rules do not authorize a self-directed change from Ozempic to Wegovy or a new dose. A qualifying benefit determination, a valid prescription and the medical decision remain distinct.
Consider two different records. A person prescribed Ozempic for type 2 diabetes should first check the drug’s ordinary Part D benefit and plan utilization rules, because Ozempic is not on the Bridge product list. Someone prescribed Wegovy for qualifying weight management may need to ask whether the CMS Bridge conditions are met, including the medical exclusions and the named tablet or injection product.
Neither example guarantees coverage: the first turns on the member’s plan and medically accepted use, while the second turns on the demonstration’s central authorization and participating pharmacy claim pathway. Ask for the precise denial or authorization status before paying or changing the prescription.
Confirm eligible Part D enrollment, actual prescribed indication, listed Bridge product and form, BMI and qualifying diagnoses as evaluated by the clinician, relevant prior Part D GLP-1 history, program authorization status and the dispenser’s ability to submit a claim. For a standard Part D route, use that plan’s benefit documents instead.
These details can change during a demonstration. This website is not CMS, an insurer, a prescriber or a pharmacy and does not determine anyone’s eligibility. It may receive separately disclosed referral compensation, which is unrelated to the federal approval process.
CMS launched the demonstration on July 1, 2026; the currently specified end date is December 31, 2027.
No. Only eligible Part D beneficiaries meeting the clinical and administrative Bridge requirements for a listed product and weight-management purpose qualify.
No. CMS lists specified Wegovy formulations, Foundayo and Zepbound KwikPen, not Ozempic, for the Bridge.
No. It applies only to qualifying supplies processed under the Bridge for eligible beneficiaries.
No. It operates outside normal Part D coverage and payment flow and has a separate authorization and processing system.
No. CMS states that the Bridge copay does not count toward Part D true out-of-pocket costs.
CMS treats type 2 diabetes as a Part D-coverable indication and imposes Bridge exclusions that do not disappear merely because the plan denies a claim.
CMS has multiple adult eligibility pathways with different BMI thresholds and specified coexisting conditions; meeting a single number alone does not guarantee qualification.
No. CMS states that coupons and discount programs cannot be applied to Medicare GLP-1 Bridge claims.